Meta-analyses of pain studies: What we have learned

Best Practice and Research: Clinical Rheumatology

Volumn 29, Issue 1, 2015, Pages 131-146

  Häuser, Winfried ^a,b   Tölle, Thomas R ^b  

^a KLINIKUM SAARBRÜCKEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chronic pain; Efficacy; Meta analysis; Nocebo response; Placebo response; Systematic review

Indexed keywords

ANALGESIC AGENT; PLACEBO;

ANALGESIA; ARTICLE; CHRONIC PAIN; CLINICAL PRACTICE; CONTROL GROUP; HUMAN; NOCEBO EFFECT; PAIN; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; STUDY DESIGN; META ANALYSIS (TOPIC);

CHRONIC PAIN; HUMANS; META-ANALYSIS AS TOPIC;

EID: 84938970240     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2015.04.021     Document Type: Review

References (65)

1. E. Walker, A.V. Hernandez, and M.W. Kattan Meta-analysis: its strengths and limitations Cleve Clin J Med 75 2008 431 439
2. Agency for Healthcare Research and Quality Effective health care program. Glossary of terms http://effectivehealthcare.ahrq.gov/index.cfm/glossary-of-terms/?pageaction=showterm&termid=70 [accessed 26.01.15]
3. A.D. Furlan, R. Reardon, C. Weppler National Opioid Use Guideline Group Opioids for chronic noncancer pain: a new Canadian practice guideline CMAJ 182 2010 923 930
4. A.D. Furlan, J.A. Sandoval, A. Mailis-Gagnon, and E. Tunks Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects CMAJ 174 2006 1589 1599
5. W. Häuser, F. Bock, P. Engeser, and et al. Recommendations of the updated LONTS guidelines: long-term opioid therapy for chronic noncancer pain Schmerz 29 2015 109 130
6. F. Petzke, P. Welsch, P. Klose, and et al. Opioids in chronic low back pain: a systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration Schmerz 29 2015 60 72
7. W. Häuser, K. Bernardy, and C. Maier Long-term opioid therapy in chronic noncancer pain: a systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks Schmerz 29 2015 96 108
8. C. Sommer, P. Welsch, P. Klose, and et al. Opioids in chronic neuropathic pain: a systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration Schmerz 29 2015 35 46
9. R. Schaefert, P. Welsch, P. Klose, and et al. Opioids in chronic osteoarthritis pain: a systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration Schmerz 29 2015 47 59
10. P. Welsch, C. Sommer, M. Schiltenwolf, and W. Häuser Opioids in chronic noncancer pain-are opioids superior to nonopioid analgesics?: a systematic review and meta-analysis of efficacy, tolerability and safety in randomized head-to-head comparisons of opioids versus nonopioid analgesics of at least four week's duration Schmerz 29 2015 85 95
11. R. Lauche, P. Klose, L. Radbruch, and et al. Opioids in chronic noncancer pain-are opioids different?: a systematic review and meta-analysis of efficacy, tolerability and safety in randomized head-to-head comparisons of opioids of at least four week's duration Schmerz 29 2015 73 84
12. US Food and Drug Administration Enhancing regulatory science - methodologies for meta-analysis www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm360080.htm [accessed 15.02.15]
13. M. Egger, and G.D. Smith Meta-analysis. Potentials and promise BMJ 315 1997 1371 1374
14. J.P.T. Higgins, and S. Green Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011] 2011 The Cochrane Collaboration Available from www.cochrane-handbook.org
15. R.D. Riley, P.C. Lambert, and G. Abo-Zaid Meta-analysis of individual participant data: rationale, conduct, and reporting BMJ 340 2010 c221
16. T. Li, M.A. Puhan, S.S. Vedula, et al. Ad Hoc Network Meta-analysis Methods Meeting Working Group Network meta-analysis-highly attractive but more methodological research is needed BMC Med 9 2011 79
17. A.J. Vickers, A.M. Cronin, A.C. Maschino, et al. Acupuncture Trialists' Collaboration Acupuncture for chronic pain: individual patient data meta-analysis Arch Intern Med 22 172 2012 1444 1453
18. W. Häuser, M. Kosseva, N. Üceyler, and et al. Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis Arthritis Care Res Hob 63 2011 808 820
19. E. Nüesch, W. Häuser, K. Bernardy, and et al. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis Ann Rheum Dis 72 2013 955 962
20. M.W. Russo How to review a meta-analysis Gastroenterol Hepatol (N Y) 3 2007 637 642
21. D. Moher, L. Shamseer, M. Clarke, et al. PRISMA-P Group Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement Syst Rev 4 2015 1
22. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman The PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269
23. B.J. Shea, J.M. Grimshaw, G.A. Wells, and et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews BMC Med Res Methodol 7 2007 10
24. R. Andrew Moore, C. Eccleston, S. Derry, et al. ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief Cochrane Pain, Palliative and Supportive Care Systematic Review Group Editors "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews Pain 15 2010 386 389
25. L.E. Chaparro, A.D. Furlan, A. Deshpande, and et al. Opioids compared to placebo or other treatments for chronic low-back pain Cochrane Database Syst Rev 8 2013 CD004959
26. Cochrane Clinical Answers, Simone Appenzeller (on behalf of Cochrane Clinical Answers Editors). In people with fibromyalgia, what are the effects of cognitive behavioral therapies? 2012. http://dx.doi.org/10.1002/cca.423.
27. S.S. Vedula, L. Bero, R.W. Scherer, and K. Dickersin Outcome reporting in industry-sponsored trials of gabapentin for off-label use N Engl J Med 361 2009 1963 1971
28. B. Hart, A. Lundh, and L. Bero Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses BMJ 344 2012 d7202
29. G. Frosi, R.D. Riley, P.R. Williamson, and J.J. Kirkham Multivariate meta-analysis helps examine the impact of outcome reporting bias in Cochrane rheumatoid arthritis reviews J Clin Epidemiol 68 2015 542 550
30. AllTrials. www.alltrials.net/find-out-more/about-alltrials/ [accessed 02.01.15].
31. European Medicines Agency Publication of clinical data www.ema.europa.eu/ema/index.jsp?curl=pages/special-topics/general/general-content-000555.jsp [accessed 15.02.15]
32. R.A. Moore, S. Derry, and P.J. Wiffen Challenges in design and interpretation of chronic pain trials Br J Anaesth 111 2013 38 45
33. R.H. Dworkin, D.C. Turk, K.W. Wyrwich, and et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations J Pain 9 2008 105 121
34. R.A. Moore, S.S. Smugar, H. Wang, and et al. Numbers-needed-to-treat analyses-do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials Pain 151 2010 592 597
35. R.M. Bennett, A.G. Bushmakin, J.C. Cappelleri, and et al. Minimal clinically important difference in the fibromyalgia impact questionnaire J Rheumatol 36 2009 1304 1311
36. L.J. Crofford, P.J. Mease, S.L. Simpson, and et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin Pain 136 2008 419 431
37. R.A. Moore What works for whom? Determining the efficacy and harm of treatments for pain Pain 154 2013 S77 S86
38. C.P. Watson, L. Vernich, M. Chipman, and K. Reed Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial Neurology 51 1998 1166 1171
39. H.J. McQuay, S. Derry, R.A. Moore, and et al. Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain Pain 135 2008 217 220
40. W. Häuser, P. Klose, P. Welsch, and et al. Methodology of the development of the updated LONTS guidelines for long-term administration of opioids in noncancer pain Schmerz 29 2015 8 34
41. A. Furlan, L.E. Chaparro, E. Irvin, and A. Mailis-Gagnon Acomparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain Pain Res Manag 16 2011 337 351
42. E. Nüesch, S. Trelle, S. Reichenbach, and et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study BMJ 341 2010 c3515
43. R.A. Moore, D. Gavaghan, M.R. Tramèr, S.L. Collins, and H.J. McQuay Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects Pain 78 1998 209 216
44. J.A. Berlin, S.C. Glasser, and S.S. Ellenberg Adverse event detection in drug development: recommendations and obligations beyond phase 3 Am J Public Health 98 2008 1366 1371
45. K. Bernardy, P. Klose, A.J. Busch, and et al. Cognitive behavioural therapies for fibromyalgia Cochrane Database Syst Rev 9 2013 CD009796
46. H. MacPherson, E. Vertosick, G. Lewith, et al. Acupuncture Trialists' Collaboration Influence of control group on effect size in trials of acupuncture for chronic pain: a secondary analysis of an individual patient data meta-analysis PLoS One 9 2014 e93739
47. R.A. Moore, S. Straube, C. Eccleston, and et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses Pain 153 2 2012 265 268
48. H.Y. Huang, E. Andrews, J. Jones, and et al. Pitfalls in meta-analyses on adverse events reported from clinical trials Pharmacoepidemiol Drug Saf 20 2011 1014 1020
49. S. Harnisch, C. Schade-Brittinger, and W. Rief Assessing adverse reactions in clinical trials Dtsch Med Wochenschr 137 2012 1421 1425
50. M. Hunsinger, S.M. Smith, D. Rothstein, and et al. Adverse event reporting in nonpharmacologic, noninterventional pain clinical trials: ACTTION systematic review Pain 155 2014 2253 2262
51. S.M. Kashikar-Zuck Psychological interventions for pediatric chronic pain - the good news and the challenges ahead Pain 148 2010 361 362
52. J.C. Andrews, H.J. Schünemann, A.D. Oxman, and et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength JClin Epidemiol 66 2013 726 735
53. D.G. Altman, and J.M. Bland Absence of evidence is not evidence of absence Aust Vet J 74 1996 311
54. W. Häuser, E. Bartram-Wunn, C. Bartram, and et al. Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors Pain 152 2011 1709 1717
55. E. Ernst, and K.L. Resch Concept of true and perceived placebo effects BMJ 311 1995 551 553
56. W. Häuser, P. Sarzi-Puttini, T.R. Tölle, and F. Wolfe Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis Clin Exp Rheumatol 30 2012 78 87
57. W. Häuser, E. Bartram-Wunn, C. Bartram, and T.R. Tölle Placebo responders in randomized controlled drug trials of fibromyalgia syndrome: systematic review and meta-analysis Schmerz 25 2011 619 631
58. W. Häuser, C. Bartram, E. Bartram-Wunn, and T. Tölle Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review Clin J Pain 28 2012 437 451
59. A. Hróbjartsson, and P.C. Gøtzsche Placebo interventions for all clinical conditions Cochrane Database Syst Rev 1 2010 CD003974
60. J. Howick, C. Friedemann, M. Tsakok, and et al. Are treatments more effective than placebos? A systematic review and meta-analysis PLoS One 8 2013 e62599
61. W. Zhang, J. Robertson, A.C. Jones, and et al. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials Ann Rheum Dis 67 2008 1716 1723
62. Initiative on Methods Measurement, and pain assessment in clinical trials (IMMPACT). Recommendations [accessed 19.02.15] www.immpact.org/publications.html
63. B.E. Wampold, T. Minami, S.C. Tierney, and et al. The placebo is powerful: estimating placebo effects in medicine and psychotherapy from randomized clinical trials JClin Psychol 61 2005 835 854
64. U. Bingel Placebo Competence Team JAMA 312 2014 693 694
65. W. Häuser, E. Hansen, and P. Enck Nocebo phenomena in medicine: their relevance in everyday clinical practice Dtsch Arztebl Int 109 2012 459 465